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Abstract
Introduction: We studied the efficacy of immunosuppressive treatment of GO in a group of patients who had been treated with anti-
thyroid drugs (the ATD group) and in another group that had undergone radioiodine therapy (the 131-I group).
Material and methods: A total of 214 patients with exacerbation of GO were studied; the ATD group consisting of 168 patients, and the 131-I 
group consisting of 46 patients. All patients were treated with methylprednisolone IV pulses (total dose 8.0 g) followed by orbital irradiation 
(20 Gy in 10 fractions). CAS and IO indices, TSH, fT4, and TRAb levels were evaluated prior to, and 1, 6, and 12 months after treatment.
Results: One month after treatment the CAS index decreased significantly in both groups, against values before treatment, p < 0.05. In 
the ATD group the median level of TRAb-0 before treatment was 5.6 IU/L (min = 0.1; max = 114.0), and 12 months later (TRAb-12) it 
was 1.4 IU/L (min = 0.1; max = 75.3) (p < 0.05). In the 131-I group the median level of TRAb-0 was 14.3 IU/L (min = 0.6; max = 90.0) vs. 
TRAb-12 of 3.65 IU/L (min = 0.1; max = 41.0) (p < 0.05). In the ATD group the median value of IO-0 before treatment was 5.0 (min = 1.0; 
max = 12.0) vs. IO-12 of 2.0 (min = 0.0; max = 8.0) (p < 0.05). In the 131-I group the median value of IO-0 was 5.0 (min = 2.0; max = 9.0) 
vs. IO-12 of 2.0 (min = 0.0; max = 6.0) (p < 0.05).
Conclusions: The severity of GO in the ATD and 131-I groups did not differ significantly over the course of observation despite differ-
ences noted in their TRAb levels. The efficacy of GO treatment did not differ between these groups. (Endokrynol Pol 2016; 67 (6): 554–561)
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Streszczenie
Wstęp: Porównano skuteczność leczenia immunosupresyjnego orbitopatii tarczycowej (GO) u pacjentów leczonych wcześniej doustnymi 
lekami tyreostatycznymi (grupa ATD) oraz u pacjentów po leczeniu radiojodem (grupa 131-I).
Materiał i metody: Przebadano 214 pacjentów z zaostrzeniem GO. Grupa ATD składała się ze 168 pacjentów leczonych lekami tyreostaty-
cznymi. Grupa 131-I składała się z 46 pacjentów leczonych radiojodem. Wszyscy pacjenci byli leczeni pulsami dożylnymi methylprednis-
olonu (łączna dawka 8,0 g), a następnie poddawani radioterapii oczodołów (20 Gy w 10 frakcjach). Indeksy CAS i IO, stężenia TSH, fT4 
oraz TRAb oceniano przed leczeniem, a następnie 1, 6 i 12 miesięcy po leczeniu.
Wyniki: W obu grupach miesiąc po leczeniu indeks CAS istotnie zmniejszył się w porównaniu z wartościami wyjściowymi, p < 0,05. 
W grupie ATD mediana stężenia TRAb-0 wynosiła 5,6 U/l (min = 0,1; max = 114,0) przed leczeniem i 1,4 U/l (min = 0,1; max = 75,3) 
(p < 0,05) 12 miesięcy po leczeniu (TRAb-12). W grupie 131-I mediany stężenia TRAb-0 i TRAb-12 wynosiły odpowiednio 14,3 IU/L (min = 0,6; 
max = 90,0) i 3,65 IU/l (min = 0,1; max = 41,0) (p < 0,05). Mediana wartości indeksu IO przed leczeniem (IO-0) w grupie ATD wynosiła 
5,0 (min = 1,0; max = 12,0), a po leczeniu (IO-12) 2,0 (min = 0,0; max = 8,0) (p < 0,05). W grupie 131-I mediany wartości IO-0 i IO-12 
wynosiły odpowiednio 5,0 (min = 2,0; max = 9,0) i 2,0 (min = 0,0; max = 6,0) (p < 0,05).
Wnioski: Stopień zaawansowania GO u pacjentów w grupie ATD i 131-I nie różnił się znamiennie statystycznie przez cały okres obser-
wacji. Mimo że stężenia TRAb w grupie 131-I zawsze przekraczały górny zakres wartości prawidłowych i były wyższe niż w grupie ATD, 
skuteczność leczenia GO w obu grupach była taka sama. (Endokrynol Pol 2016; 67 (6): 554–561)
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Graves’ orbitopathy (GO) is a rare disease associated 
with autoimmune disorder — Graves’ disease (GD), 
with a prevalence of about 25% in GD patients [1–3]. 
According to Tanda et al. [4], some 20% of patients suf-
fering from Graves’ disease have inactive or mild GO, 
6% have active and moderate-to-severe GO, and only 
0.3% develop dysthyroid optic neuropathy (DON). The 
remaining 73.7% of Graves’ patients are free of ocular 
symptoms. The prevalence of GO tends to decline over 
the years, perhaps due to the decrease in smoking habits 
or to earlier diagnosis [4–7]. As only limited groups of 
GO patients are available for randomised clinical trials 
(RCTs), precise GO pathogenesis and targeted treat-
ment remain uncertain [2, 8]. It is believed that higher 
TRAb titres are present in patients with more severe 
GO [9, 10]. Radioiodine treatment is associated with 
an increased risk of ophthalmopathy and more severe 
course than that after antithyroid medication [11, 12]. 
After radioiodine, persistent elevated TRAb levels were 
observed for over five years [13, 14]. 
The aim of our study was to evaluate the efficacy of 
immunosuppressive treatment of GO in patients who 
had earlier been treated with anti-thyroid drugs (the 
ATD group) or who had undergone radioiodine therapy 
(the 131-I group).
Material and methods
Over the years 2000–2008 more than four hundred 
patients were admitted to our Endocrinology Depart-
ment of the University Hospital, presenting with exac-
erbation of the eye syndrome in the course of Graves’ 
disease. The patients who voluntarily participated in 
this prospective observational study signed their writ-
ten consent and underwent follow-up for a period of 
12 months after completion of their GO treatment. 
The drop-out rate was 46% (i.e. of 400 enlisted patients 
214 completed this study). The study was approved by the 
Bioethics Committee of the Jagiellonian University. 
Before admission to our Department, patients had 
been treated elsewhere for hyperthyroidism, either 
with anti-thyroid drugs (ATD group) or with radio-
iodine (131 I-group). The ATD group consisted of 
168 patients, 119 females and 49 males, of mean age 
52.2 ± 11.2 years. The 131-I group consisted of 46 patients, 
37 females and 9 males, of mean age 52.1 ± 13.3 years. 
All patients were evaluated by the same ophthalmolo-
gist. Severity and activity of GO were graded using the 
Clinical Activity Score (CAS) [15] ranging between 0 and 
7 and the NOSPECS (No signs or symptoms; Only signs; 
Soft tissue involvement; Proptosis; Extraocular muscle 
involvement; Corneal involvement; Sight loss) clas-
sification [16], as expressed by the Orbitopathy Index 
(IO), ranging between 0 and 15. Orbital CT evaluations 
were performed for all patients. Patients were rendered 
euthyroid prior to application of methylprednisolone 
pulses. CAS and IO indices, TSH, FT4, and anti-TSH 
receptor antibody (TRAb) levels were evaluated prior to, 
and 1, 6, and 12 months after treatment. Patients were 
treated with intravenous methylprednisolone pulses 
(1 g for two consecutive days each week to a total dose 
of 8.0 g) followed by orbital irradiation a month later 
(20 Gy total dose in 10 daily fractions). No major side 
effects of glucocorticoid therapy were observed.
The ATD group
The mean TSH and fT4 concentration before GO treat-
ment was 2.34 ± 8.81 µU/mL and 18.34 ± 12.24 pmol/mL, 
respectively. Methimazole was used in 133 patients 
and L-thyroxin in 131 patients. Thyroidectomy was 
performed in 26 (15.8%) patients. Enlargement of the 
extraocular muscles was observed in the CT-scans of 
85.1% of patients. The mean time of GO duration was 
12.5 ± 20.3 months. The mean time of hyperthyroid-
ism treatment was 31.5 ± 52.4 months. After IV pulses 
41.1% of patients had to continue their therapy with 
oral glucocorticosteroids while awaiting their radio-
therapy, during radiotherapy, and up to two months 
post therapy. 
The 131-I group
Radioiodine treatment was offered to patients with IO 
< 3 and CAS < 3. In this group, TSH blood concentra-
tion prior to 131-I treatment was 0.24 ± 0.58 µU/mL. 
The mean radioiodine activity administered was 
496 ± 141 MBq. On admission to our Clinic due to 
GO, 35 of 46 patients (76%) were hypothyroid (mean 
TSH concentration 23.9 ± 24.5 µU/mL). To maintain 
euthyroidism, patients were treated with L-thyroxin. 
Prior to their radioiodine treatment thyroidectomy 
was performed in 17.4% of patients. Eight patients 
received I-131 treatment twice and one patient three 
times. In 87% of patients, enlargement of extraocular 
muscles was observed in orbital CT. The mean time of 
GO duration was 11.9 ± 17.8 months. The mean time 
of hyperthyroidism treatment was 72.3 ± 67.8 months. 
After IV methylprednisolone pulses, 28.3% of patients 
had to continue their therapy with oral glucocortico-
steroids until radiotherapy, during radiotherapy, and 
up to two months post therapy. 
Laboratory tests
TSH concentrations were measured using radioimmu-
noassay (RIA) by Byk-Mallincrodt and immunoradio-
metric assay (IRMA) by Brahms GmbH, (normal range 
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using electrochemiluminescence immunoassay (ECLIA) 
by Roche Diagnostics (normal range 12–22.0 pmol/L). 
TRAb concentrations were measured using radioim-
munoreceptor assay (RRA, TRAK human) by Brahms 
GmbH (normal value < 2.0 IU/L).
Statistical analysis
We evaluated the efficacy of GO treatment. The ATD 
and 131-I groups were compared in terms of GO activ-
ity and severity, and with respect to TRAb levels dur-
ing the follow-up period. Descriptive and inferential 
statistical data analysis was performed. Arithmetic 
means, standard deviations (± SD), and medians (min, 
max) were calculated. The Shapiro-Wilk test was used 
to test the normal distribution of data. For data with 
normal distribution, Student’s t-test was applied. For 
data with non-normal distribution, U-Mann-Whitney 
and Wilcoxon signed-rank tests were applied. Since for 
non-Gaussian distributions the t-test may be valid if the 
number of samples exceeds 50 due to the property of 
robustness, the t-test was also applied in our analysis. 
The assumed level of significance was a < 0.05. SoftStat 
Statistica, version 9.0 software was used.
Results
The ATD group
In this group, the median value of the CAS-0 index prior 
to treatment and CAS-1 one month after treatment was 
4 points (min = 0, max = 7) and 1 point (min = 0, max = 7), 
respectively (p < 0.05) (Fig. 1, Table I). 
The median IO-0 values in the ATD group prior to 
treatment and after 12 months (IO-12) of observation 
were 5 points (min = 1, max = 12) and 2 points (min = 0, 
max = 8), respectively (p < 0.05) (Table I). As based on 
t-test for paired samples and Wilcoxon signed-rank test, 
the IO values after 1, 6, and 12 months of observation 
were significantly lower than those before treatment 
(p < 0.05).
In the ATD group, no differences between median 
IO-0 values for female and male patients were observed: 
5 points (min = 2, max = 12) and 5 points (min = 1, 
max = 12), respectively. However, after 12 months, these 
differences were significant: median IO-12 values were 
2 points (min = 0, max = 7) and 3 points (min = 0, max 
= 8), respectively. Indeed, this difference remained 
significant during the follow-up period. 
Before treatment, over 90% of patients experienced 
soft tissue swelling and extraocular muscle dysfunction. 
Within this subgroup, 30% developed severe (grade 3) 
symptoms. Proptosis was diagnosed in 53% of patients, 
of whom 6% experienced marked proptosis. Corneal 
pathology was observed in 21.4% of patients including 
severe damage in 1.2% of patients. Dysthyroid optic 
neuropathy (DON) was observed in 8.3% of patients, 
including severe DON, detected in 3.0% of patients. 
Aggravation of GO was observed in three patients 
one month after and in four patients six months after 
completion of treatment. 
After 12-month follow-up upper lid retraction, soft 
tissue swelling, or extraocular muscle dysfunction 
(mainly grades 1 or 2) were present in 52.3%, 40.5%, 
and 60.7% of patients, respectively. In 46.7% of patients 
IO of 2 or 3 was stated, hence they still experienced 
symptoms of mild Graves’ orbitopathy. 
In the ATD group, TSH and fT4 concentrations 
did not differ significantly throughout the 12-month 
follow-up. The median value of TRAb-0 level was 5.6 
IU/L (min = 0.1; max = 114.0) vs. 1.4 IU/L (min = 0.1; 
max = 75.3) for TRAb-12 (p < 0.05). TRAb concentra-
tions at 1, 6, and 12 months after treatment were lower 
than the baseline level (Table I), (Wilcoxon signed-rank 
test, p < 0.05). Since the distribution of TRAb values was 
right-skewed, we took logarithms of these values and 
analysed their distribution using the Shapiro-Wilk test, 
followed by the t-test (p < 0.05) (Fig. 2).
The 131-I group
In this group, the median values of CAS-0 index prior 
to treatment and CAS-1 one month after treatment 
were 4 (min = 2, max = 7) and 2 (min = 0, max = 6), 
respectively (p < 0.05)  (Fig. 1, Table I). 
The median values of IO-0 in this group prior to 
treatment and after 12 months (IO-12) of observation 
were 5 (min = 2, max = 12) and 2 (min = 0, max = 6), 
respectively (p < 0.05) (Table I). Based on the t-test for 
paired samples and the Wilcoxon signed-rank test, IO 
values after 1, 6, and 12 months of observation were sig-
nificantly lower than those before treatment (p < 0.05).
About 90% of patients in this group presented 
with upper eyelid retraction, soft tissue swelling and 
extraocular muscle dysfunction before treatment. 
Among them, 21.7% and 24.0% had severe soft tissue 
swelling and extraocular muscle dysfunction (grade 3), 
respectively. Proptosis was present in 54.3% of pa-
tients, but none of them developed severe proptosis. 
Corneal damage was observed in 19.6% of patients. No 
symptoms of DON were found in this group. Aggrava-
tion of GO was observed in three patients one month 
after and in one patient six months after completion 
of the treatment.
After 12-month follow-up, upper lid retraction, soft 
tissue swelling and extraocular muscle dysfunction 
remained with various degrees of severity (mainly 
grade 1 and 2) in 56.5%, 43.5%, and 67.4% of patients, 
respectively. 20.5% of patients had an IO of 4, hence 
they still experienced symptoms of moderately severe 
orbitopathy. 
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Table I. Comparison of TRAb levels and of IO and CAS scores in the ATD and 131-I groups
Tabela I. Porównanie stężenia TRAb, indeksów IO i CAS w grupie ATD i 131-I
Parameter ATD median (min-max) 131-I median (min-max) Difference p-value
TRAb 0 [IU/L] 5.6 (0.1–114.0) 14.3 (0.6–90.0) 0.0013
TRAb 1 [IU/L] 2.2 (0.01–51.9) 7.7 (0.1–80.0) 0.0001
TRAb 6 [IU/L] 1.6 (0.1–78.8) 4.65 (0.1–96.0) 0.0009
TRAb 12 [IU/L] 1.4 (0.1–75.3) 3.65 (0.1–41.0) 0.0129
IO 0 5.0 (1.0–12.0) 5.0 (2.0–9.0) 0.7155
IO 1 3.0 (0.0–10.0) 4.0 (1.0–8.0) 0.1610
IO 6 3.0 (0.0–9.0) 3.0 (0.0–7.0) 0.8657
IO 12 2.0 (0.0–8.0) 2.0 (0.0–6.0) 0.9461
CAS 0 4.0 (0.0–7.0) 4.0 (2.0–7.0) 0.1588
CAS 1 1.0 (0.0–7.0) 2.0 (0.0–6.0) 0.0151
In the 131-I group, TSH and fT4 concentrations re-
mained within normal range and did not differ signifi-
cantly throughout the 12-month follow-up. The median 
TRAb-0 value prior to treatment was 14.3 IU/L (min = 0.6; 
max = 90.0) vs. TRAb-12 of 3.65 IU/L (min = 0.1; max = 
=41.0) (p < 0.05) (Table I). TRAb concentrations after 1, 
6, and 12 months of treatment were significantly lower 
than the baseline level, as shown by t-test for paired 
Figure 1. Distribution of Clinical Activity Score (CAS) prior to and 1 month after GO treatment in the ATD and 131-I groups
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samples applied to natural logarithms of variables 
(Fig. 3) and Wilcoxon signed rank test (p < 0.05). 
Comparison between ATD and 131-I groups 
(Table I)
The activity and severity of GO in patients of the 
ATD and 131-I groups did not differ, despite differences 
in TRAb levels (Table I). We note that the percentage 
of patients after thyroidectomy in both groups did not 
differ significantly.
After treatment, CAS-1 decreased significantly in 
both groups, with respect to CAS-0 (p < 0.05). The 
CAS-1 score was significantly higher in the 131-I group 
(p < 0.05).
Independently of the method of analysis chosen 
(mean or median), TRAb levels in the 131-I group were 
always above normal level and significantly higher 
than those in the ATD group throughout the follow-up 
period (p < 0.05) (Table I, Fig. 4). 
In the ATD group the course of median TRAb 
level (y) vs. time, in months (x), could be approximated 
by the equation y = 2.6354–1.4099*log10(x), while in 
the 131-I group the respective approximation was 
y = 7.4554–3.4544*log10(x), as shown in Figure 4. 
There was no significant difference in the course of 
IO between the ATD and 131-I groups (Table I). In the 
ATD group the course of the median IO (y) vs. time, 
in months (x), could be approximated by the expres-
sion y = 4.0812*exp (–0.0595*x). In the 131-I group the 
course of the median IO could be approximated by y 
= 4.6481*exp (–0.0713*x). The IO vs. time dependences 
over 12 months in both groups are shown in Figure 5. 
Before treatment there was no significant differ-
ence between both groups with respect to age, sex, 
GO duration, IO, CAS-0 and fT4 levels. In the 131-I 
group, hyperthyroidism was significantly extended in 
time (p < 0.05), and pre-treatment levels of TSH were 
significantly higher than in the ATD group (6.7 ± 16.3 
vs. 2.34 ± 8.81 U/L, p < 0.05). 
Figure 2. TRAb concentration prior to, and 1, 6, and 12 months 
after treatment in the ADT group (t-test for paired samples, natural 
logarithms of variables)
Rycina 2. Stężenie TRAb przed leczeniem oraz po 1, 6, i 12 
miesiącach w grupie ATD (test t dla prób zależnych dla zmiennych 
zlogarytmowanych)
Figure 3. TRAb concentration prior to, and 1, 6, and 12 months 
after treatment in the 131-I group (t-test for paired samples, 
natural logarithms of variables)
Rycina 3. Stężenie TRAb przed leczeniem oraz po 1, 6, i 12 
miesiącach w grupie 131-I (test t dla prób zależnych dla zmiennych 
zlogarytmowanych)
Figure 4. Time-dependence of TRAb concentration over 12 months 
in the ATD group, y = 2.6354–1.4099*log10(x), and in the 131-I 
group, y = 7.4554–3.4544*log10(x)
Rycina 4. Porównanie zmian stężenia TRAb w grupie ATD 
opisane równaniem y = 2.6354–1.4099*log10(x) i w grupie 
131-I opisane równaniem y = 7.4554–3.4544*log10(x) w czasie 
12-miesięcznej obserwacji
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It is well known that radioiodine treatment may prolong 
thyrotropin receptor (TSH-R) autoimmunity in patients 
with Graves’ disease, leading to de novo orbitopathy oc-
currence or to exacerbation of symptoms of concurrent 
GO. The likely pathogenesis of this phenomenon is the 
sudden release of thyroid antigens by 131-I-damaged 
thyroid cells, causing an increase in the production of 
autoantibodies, including TRAb [11, 13]. It is estimated 
that GO aggravation after 131-I treatment affects up 
to 20% of patients [11] and is more predominant in 
patients who had earlier manifested eye symptoms 
[2, 8] or in those with prolonged hypothyroidism fol-
lowing radioiodine treatment [17]. Male patients are 
more prone to GO exacerbation [18]. We also found 
significantly higher mean and median IO values in men 
in our ATD group over the follow-up period, suggest-
ing a more severe and resistant course of GO in male 
patients. However, this trend was not observed in our 
131-I group, presumably due to the small number of 
men (19.6%) in this group. 
In a multi-centre study by Prummel et al. conducted 
in 2003 [19], proptosis was observed in 63% of newly 
referred patients with GO, while keratopathy was 
detected in 16% and optic nerve involvement in 21% 
of their patients. In our study, the percentage of the 
above-mentioned pathologies was comparable, except 
for DON, diagnosed in only 8.3% patients of our ATD 
group. The median values of IO prior to treatment 
and after 12 months of observation were 5 and 2, re-
spectively, in both groups, thus the two groups did not 
differ with respect to severity, neither on admission to 
our Department nor at the end of the follow-up period, 
which is in agreement with a retrospective study con-
ducted by Sisti et al. [20]. However, it is believed that 
patients after radioiodine treatment tend to develop 
more severe GO [11].
Thyroidectomy may have an impact on the course 
of GO. Weber et al. [21] observed either improvement or 
subsidence of eye symptoms after surgery. In contrast, 
our patients - despite their previous thyroidectomy — 
were still hyperthyroid and, for that reason, had been 
treated with methimazole or 131-I before admission 
to our Department to treat their GO exacerbation. 
Therefore, we assumed that prior thyroidectomy in 
these patients would not affect the efficacy of our GO 
treatment. We note that since the percentages of oper-
ated patients in the ATD and the 131-I groups did not 
differ, both groups are comparable with respect to the 
subject of our study.
Our treatment protocol, established in the year 2000, 
was based on our clinical experience and on published 
work available at the time, as summarised in the review 
of Zang et al. [22]. Like Macchia et al. in 2001 [23], we 
administered 1 g of methylprednisolone for two con-
secutive days each week, but we did not exceed the 
cumulative dose of 8.0 g. 
In 2008 in the Thyroid journal, following reported 
cases of acute liver failure associated with high cu-
mulative doses of methylprednisolone, EUGOGO 
recommended not to exceed a cumulative dose of 
methylprednisolone of 8.0 g [24]. By that time, we had 
completed our patient recruitment.
For orbital irradiation we applied a cumulative dose 
of 20 Gy, which was in line with the studies conducted by 
Marcocci et al. in 2001 [25] and by Ng et al. in 2005 [26].
We used a combination of methylprednisolone 
pulses followed by orbital irradiation, with good clinical 
outcome, low rate of recurrence, and no major clinical 
side effects. This treatment had already been proposed 
in 1983 by Bartalena et al. [27], who reported a better 
outcome of the combined therapy. Several studies con-
firmed the efficacy of orbital irradiation as based on the 
meta-analysis by Viani et al. [28], although Otsuka et 
al. [29] found no significant differences in terms of the 
therapeutic effect between groups treated with steroid 
pulses with or without orbital irradiation. There are no 
large RCTs comparing the advantage of this combined 
treatment over IV glucocorticosteroids alone [28, 30, 31]. 
As reported in a randomised study, lower orbital doses 
of 12 Gy were sufficient in reducing soft tissue changes, 
and higher doses were required in patients with ocular 
motility impairment [32]. It is generally accepted that 
orbital irradiation should be considered in patients with 
Figure 5. Time-dependence of the IO over 12 months in the ATD 
group, y = 4.0812*exp (–0.0595*x), and in the 131-I group, y = 
4.6481*exp (–0.0713*x)
Rycina 5. Porównanie zmian indeksów IO w grupie ATD opisane 
równaniem y = 4.0812*exp(–0.0595*x) i w grupie 131-I opisane 
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diplopia and impaired motility [24, 26, 30, 32]. This has 
been confirmed by our clinical observation. 
We found our treatment to be effective, since the rate 
of recurrence was low. Both groups responded well, 
and decreases in CAS and IO indices were significant. 
However, the CAS-1 score was significantly higher in 
the 131-I group, which might suggest that in patients 
with GO after radioiodine treatment glucocorticoid 
therapy is less effective. Following a recent multicentre 
randomised control trial [33], lower doses of IV gluco-
corticoids have been suggested. The efficacy and safety 
of different IV glucocorticosteroid therapy protocols 
are still under debate. Presently, there are no generally 
accepted recommendations or guidelines for treatment 
of GO [20, 34–36].
Elevation of TRAb blood concentration is an im-
portant GO risk factor [9]. TRAb levels increase after 
radioiodine treatment and remain elevated over con-
siderably longer periods than in patients undergoing 
ATD therapy or surgery [10, 13, 14]. In our study, TRAb 
levels in the I-131 group were systematically above 
normal level and were always higher than those in 
the ATD group. In particular, we note that in our ATD 
group, TRAb levels returned to normal within one 
month after treatment. 
We also note that despite the differences in TRAb 
levels, the efficacy of the applied immunosuppressive 
treatment was comparable in both studied groups. It 
is believed that higher TRAb titres are associated with 
more severe Graves’ orbitopathy [9, 10]. However, this 
was not confirmed by our study. On the contrary, we 
found no statistically significant difference between 
the distribution of IO (which is relevant to the severity 
of GO) in the ATD and 131-I groups over respective 
time intervals. 
Conclusions 
Treatment of Graves’ Orbitopathy in its moderate to 
severe form remains difficult. 
GO severity in the ATD and in the 131-I group of 
patients did not differ significantly over the course of 
their observation. 
Although TRAb levels in the 131-I group were al-
ways above normal level and higher than those in the 
ATD group; the efficacy of GO treatment in both groups 
did not differ significantly. 
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